Ling Mao1, Huijuan Jin1, Mengdie Wang1, Yu Hu2, Shengcai Chen1, Quanwei He1, Jiang Chang3, Candong Hong1, Yifan Zhou1, David Wang4, Xiaoping Miao3, Yanan Li1, Bo Hu1. 1. Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 2. Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 3. Department of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 4. Neurovascular Division, Department of Neurology, Barrow Neurological Institute, Saint Joseph's Hospital and Medical Center, Phoenix, Arizona.
Abstract
Importance: The outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, is serious and has the potential to become an epidemic worldwide. Several studies have described typical clinical manifestations including fever, cough, diarrhea, and fatigue. However, to our knowledge, it has not been reported that patients with COVID-19 had any neurologic manifestations. Objective: To study the neurologic manifestations of patients with COVID-19. Design, Setting, and Participants: This is a retrospective, observational case series. Data were collected from January 16, 2020, to February 19, 2020, at 3 designated special care centers for COVID-19 (Main District, West Branch, and Tumor Center) of the Union Hospital of Huazhong University of Science and Technology in Wuhan, China. The study included 214 consecutive hospitalized patients with laboratory-confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 infection. Main Outcomes and Measures: Clinical data were extracted from electronic medical records, and data of all neurologic symptoms were checked by 2 trained neurologists. Neurologic manifestations fell into 3 categories: central nervous system manifestations (dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, and seizure), peripheral nervous system manifestations (taste impairment, smell impairment, vision impairment, and nerve pain), and skeletal muscular injury manifestations. Results: Of 214 patients (mean [SD] age, 52.7 [15.5] years; 87 men [40.7%]) with COVID-19, 126 patients (58.9%) had nonsevere infection and 88 patients (41.1%) had severe infection according to their respiratory status. Overall, 78 patients (36.4%) had neurologic manifestations. Compared with patients with nonsevere infection, patients with severe infection were older, had more underlying disorders, especially hypertension, and showed fewer typical symptoms of COVID-19, such as fever and cough. Patients with more severe infection had neurologic manifestations, such as acute cerebrovascular diseases (5 [5.7%] vs 1 [0.8%]), impaired consciousness (13 [14.8%] vs 3 [2.4%]), and skeletal muscle injury (17 [19.3%] vs 6 [4.8%]). Conclusions and Relevance: Patients with COVID-19 commonly have neurologic manifestations. During the epidemic period of COVID-19, when seeing patients with neurologic manifestations, clinicians should suspect severe acute respiratory syndrome coronavirus 2 infection as a differential diagnosis to avoid delayed diagnosis or misdiagnosis and lose the chance to treat and prevent further transmission.
Importance: The outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, is serious and has the potential to become an epidemic worldwide. Several studies have described typical clinical manifestations including fever, cough, diarrhea, and fatigue. However, to our knowledge, it has not been reported that patients with COVID-19 had any neurologic manifestations. Objective: To study the neurologic manifestations of patients with COVID-19. Design, Setting, and Participants: This is a retrospective, observational case series. Data were collected from January 16, 2020, to February 19, 2020, at 3 designated special care centers for COVID-19 (Main District, West Branch, and Tumor Center) of the Union Hospital of Huazhong University of Science and Technology in Wuhan, China. The study included 214 consecutive hospitalized patients with laboratory-confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 infection. Main Outcomes and Measures: Clinical data were extracted from electronic medical records, and data of all neurologic symptoms were checked by 2 trained neurologists. Neurologic manifestations fell into 3 categories: central nervous system manifestations (dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, and seizure), peripheral nervous system manifestations (taste impairment, smell impairment, vision impairment, and nerve pain), and skeletal muscular injury manifestations. Results: Of 214 patients (mean [SD] age, 52.7 [15.5] years; 87 men [40.7%]) with COVID-19, 126 patients (58.9%) had nonsevere infection and 88 patients (41.1%) had severe infection according to their respiratory status. Overall, 78 patients (36.4%) had neurologic manifestations. Compared with patients with nonsevere infection, patients with severe infection were older, had more underlying disorders, especially hypertension, and showed fewer typical symptoms of COVID-19, such as fever and cough. Patients with more severe infection had neurologic manifestations, such as acute cerebrovascular diseases (5 [5.7%] vs 1 [0.8%]), impaired consciousness (13 [14.8%] vs 3 [2.4%]), and skeletal muscle injury (17 [19.3%] vs 6 [4.8%]). Conclusions and Relevance: Patients with COVID-19 commonly have neurologic manifestations. During the epidemic period of COVID-19, when seeing patients with neurologic manifestations, clinicians should suspect severe acute respiratory syndrome coronavirus 2 infection as a differential diagnosis to avoid delayed diagnosis or misdiagnosis and lose the chance to treat and prevent further transmission.
Authors: Claudio Cabello-Verrugio; María Gabriela Morales; Juan Carlos Rivera; Daniel Cabrera; Felipe Simon Journal: Med Res Rev Date: 2015-03-11 Impact factor: 12.944
Authors: Yaseen M Arabi; Hanan H Balkhy; Frederick G Hayden; Abderrezak Bouchama; Thomas Luke; J Kenneth Baillie; Awad Al-Omari; Ali H Hajeer; Mikiko Senga; Mark R Denison; Jonathan S Nguyen-Van-Tam; Nahoko Shindo; Alison Bermingham; James D Chappell; Maria D Van Kerkhove; Robert A Fowler Journal: N Engl J Med Date: 2017-02-09 Impact factor: 91.245
Authors: Joshua P Metlay; Grant W Waterer; Ann C Long; Antonio Anzueto; Jan Brozek; Kristina Crothers; Laura A Cooley; Nathan C Dean; Michael J Fine; Scott A Flanders; Marie R Griffin; Mark L Metersky; Daniel M Musher; Marcos I Restrepo; Cynthia G Whitney Journal: Am J Respir Crit Care Med Date: 2019-10-01 Impact factor: 21.405
Authors: Shuo Su; Gary Wong; Weifeng Shi; Jun Liu; Alexander C K Lai; Jiyong Zhou; Wenjun Liu; Yuhai Bi; George F Gao Journal: Trends Microbiol Date: 2016-03-21 Impact factor: 17.079
Authors: R Hanafi; P-A Roger; B Perin; G Kuchcinski; N Deleval; F Dallery; D Michel; L Hacein-Bey; J-P Pruvo; O Outteryck; J-M Constans Journal: AJNR Am J Neuroradiol Date: 2020-06-18 Impact factor: 3.825
Authors: Anuja Java; Anthony J Apicelli; M Kathryn Liszewski; Ariella Coler-Reilly; John P Atkinson; Alfred Hj Kim; Hrishikesh S Kulkarni Journal: JCI Insight Date: 2020-08-06
Authors: A Pons-Escoda; P Naval-Baudín; C Majós; A Camins; P Cardona; M Cos; N Calvo Journal: AJNR Am J Neuroradiol Date: 2020-06-11 Impact factor: 3.825
Authors: F D'Amore; G Vinacci; E Agosti; L P Cariddi; A V Terrana; F A Vizzari; M Mauri; A Giorgianni Journal: AJNR Am J Neuroradiol Date: 2020-07-30 Impact factor: 3.825